As of today (2024-04-19), Graphite Bio's share price is $3.18. Graphite Bio's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.17. Hence, Graphite Bio's Price to Tangible Book Ratio of today is 1.00.
The historical rank and industry rank for Graphite Bio's Price-to-Tangible-Book or its related term are showing as below:
GRPH'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1 Med: 5.79 Max: 13.14
Current: 1
During the past 5 years, Graphite Bio's highest Price to Tangible Book Ratio was 13.14. The lowest was 1.00. And the median was 5.79.
GRPH's Price-to-Tangible-Book is ranked better than 82.5% of 1223
companies
in the Biotechnology industry
Industry Median: 2.7
vs GRPH: 1.00
A closely related ratio is called PB Ratio. As of today, Graphite Bio's share price is $3.18. Graphite Bio's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.17. Hence, Graphite Bio's P/B Ratio of today is 1.00.
Graphite Bio Price-to-Tangible-Book Historical Data
The historical data trend for Graphite Bio's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Graphite Bio Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
-
13.14
4.57
5.79
Graphite Bio Quarterly Data
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
4.57
3.61
4.71
4.93
5.79
Competitive Comparison
For the Biotechnology subindustry, Graphite Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Graphite Bio's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Graphite Bio's Price-to-Tangible-Book falls into.
Graphite Bio Price-to-Tangible-Book Calculation
Graphite Bio's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Graphite Bio Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Graphite Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 